Real-world Data on Voclosporin for the Treatment of Lupus Nephritis Including Use of Concomitant Biologic Therapies: An Analysis of the Enlight-LN Registry (LUPUS 2026) - Feb 17, 2026 - Abstract #PO:09:248; 25; Pres time: Mar 6, 2026; 07:30 AM - 07:30 PM; Location: Poster Area; P | "In the Phase 3 AURORA studies, voclosporin plus mycophenolate mofetil and low-dose glucocorticoids led to significant reductions in proteinuria while maintaining a stable estimated glomerular filtration rate (eGFR) for up to 3 years of follow-up...Median (range) urine protein creatinine ratio (UPCR) was 2.3 (0.1-16.8) g/g; 38.2% of patients had baseline UPCR greater than or equal to 3 g/g.There were 83 (36.2%) patients on voclosporin who concomitantly received treatment with a biologic including belimumab (28.4%), rituximab (4.8%), anifrolumab (3.9%) and obinutuzumab (1.3%)...This is notable given the unique and possibly synergistic effects of these agents on the immune system. Additional analysis of the registry data will provide further clinical and mechanistic insights into the use of these multi-targeted therapeutic approaches."
Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis
|
|
Vanessa Birardi; Mohammad Kamgar; Laura Geraldino-Pardilla; Leanna M Wise; Niloofar Nobakht; Barbara Mcintosh; Ernie Yap; Ronald Flauto
|